NCI UC12N01 / NCI 9165 / UC 12-1359: A randomized phase II trial of ARQ 197 (tivantinib)/cetuximab versus cetuximab in patients with recurrent/metastatic head and neck cancer: Subproject for Institution # SP0012448

  • Kuzel, Timothy Michael (PD/PI)
  • Agulnik, Mark (Co-Investigator)

Project: Research project

Project Details

StatusFinished
Effective start/end date9/30/12 → 9/22/16

Funding

  • The University of Chicago (5-27050 / HHSN261201100071C)
  • National Cancer Institute (5-27050 / HHSN261201100071C)